These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 30361152

  • 1. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J, Yeung SJ, Chaftari PS.
    Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [Abstract] [Full Text] [Related]

  • 2. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 3. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 01; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 4. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Sep 01; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 5. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
    Kichloo A, Albosta MS, McMahon S, Movsesian K, Wani F, Jamal SM, Aljadah M, Singh J.
    J Investig Med High Impact Case Rep; 2020 Sep 01; 8():2324709620951339. PubMed ID: 32830561
    [Abstract] [Full Text] [Related]

  • 6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Sep 01; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 7. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 01; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 8. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK, Margull J.
    Tidsskr Nor Laegeforen; 2019 Feb 26; 139(4):. PubMed ID: 30808100
    [No Abstract] [Full Text] [Related]

  • 9. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
    Peyrony O, Ellouze S, Fontaine JP, Mohamadou I, Zafrani L.
    Am J Emerg Med; 2020 Feb 26; 38(2):408.e3-408.e4. PubMed ID: 31759780
    [Abstract] [Full Text] [Related]

  • 10. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC, Kosova K, Bohne AS, Schreiber S, Hauschild A.
    Eur J Cancer; 2020 Oct 29; 138():169-171. PubMed ID: 32890812
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Checkpoint inhibitors in the emergency department.
    Bachmeier CA, Morton A.
    Emerg Med Australas; 2019 Apr 29; 31(2):288-289. PubMed ID: 30690867
    [No Abstract] [Full Text] [Related]

  • 15. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN, Kudinov AE, Dulaimi E, Boumber Y.
    BMC Cancer; 2019 Apr 24; 19(1):379. PubMed ID: 31018834
    [Abstract] [Full Text] [Related]

  • 16. Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy.
    Luong B, Koch G, Trivedi K, Ramachandran K.
    Am J Ther; 2019 Apr 24; 31(4):e474-e475. PubMed ID: 38976534
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
    Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F.
    Cancer Immunol Immunother; 2017 Jan 24; 66(1):25-32. PubMed ID: 27761609
    [Abstract] [Full Text] [Related]

  • 19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.